Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.53 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.53 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.53 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 10/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 9/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | FADS1 | O60427 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13955562 | 0.85 | AXL (0.50) | AXLMKNK1MKNK2PDE4APDE4B | |
| SCHEMBL23515581 | 0.80 | AXL (0.49) | AXLMKNK1MKNK2PDE4APDE4B | |
| SCHEMBL24292896 | 0.80 | AXL (0.49) | AXLMKNK1MKNK2PDE4APDE4B | |
| SCHEMBL14087174 | 0.78 | AXL (0.46) | AXLMKNK1MKNK2PDE4APDE4B | |
| SCHEMBL6642089 | 0.74 | AXL (0.59) | AXLMKNK1MKNK2PDE4APDE4B | |
| SCHEMBL21567437 | 0.73 | AXL (0.49) | AXLMKNK1MKNK2PDE4APDE4B | |
| SCHEMBL10171315 | 0.72 | ADORA2A (0.58) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL17471783 | 0.72 | ADORA2A (0.49) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL20072472 | 0.72 | AXL (0.47) | AXLMKNK1MKNK2PDE4APDE4B | |
| SCHEMBL20609542 | 0.72 | AXL (0.47) | AXLMKNK1MKNK2PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3765458-B1 | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC (US) | 2023-01-11 | — | — | EP | disclosed |
| US-9670196-B2 | Thiazole-substituted aminoheteroaryls as Spleen Tyrosine Kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9650391-B2 | N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-20130029982-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, LLC (US) | 2013-01-31 | — | — | US | disclosed |
| US-20120329776-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. | 2012-12-27 | — | — | US | disclosed |
| US-8293729-B2 | Compounds, pharmaceutical composition and methods relating thereto | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| US-8278320-B2 | Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-02 | — | — | US | disclosed |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2012-05-17 | — | — | US | disclosed |
| US-20110263605-A1 | Azabicyclo[2.2.1]Heptane Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-27 | — | — | US | disclosed |
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-07 | — | — | US | disclosed |
| US-20100331348-A1 | TROPANE DERIVATIVES USEFUL AS PESTICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20080188474-A1 | e.g. 1-phenyl-N3-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-1H-1,2,4-triazole-3,5-diamine; receptor protein tyrosine kinase (AXL) antagonist; antiinflammatory, anticarcinogenic , antidiabetic agent; rheumatoid arthritis, vascular disease; breast, renal, endometrial, ovarian carcinoma, or myeloid leukemia | RIGEL PHARMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080182862-A1 | N3-HETEROARYL SUBSTITUTED TRIAZOLES AND N5-HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263605-A1 | Azabicyclo[2.2.1]Heptane Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA2, CHRNA5 | AXL 1586/4885MKNK1 1891/4885MKNK2 1417/4885 |
| US-20130029982-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | AXL 1068/4885MKNK1 122/4885MKNK2 137/4885 |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | AXL 1068/4885MKNK1 122/4885MKNK2 137/4885 |
| US-20080182862-A1 | N3-HETEROARYL SUBSTITUTED TRIAZOLES AND N5-HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, ERBB3 | AXL 1/4885MKNK1 446/4885MKNK2 253/4885 |
| US-20100331348-A1 | TROPANE DERIVATIVES USEFUL AS PESTICIDES | DDT, ACHE, TPM3 | AXL 2407/4885MKNK1 4056/4885MKNK2 4182/4885 |
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | MC2R, REN, CYP11B2 | AXL 3212/4885MKNK1 4445/4885MKNK2 4492/4885 |
| US-20120329776-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | AXL 1103/4885MKNK1 87/4885MKNK2 88/4885 |
| US-20080188474-A1 | e.g. 1-phenyl-N3-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-1H-1,2,4-triazole-3,5-diamine; receptor protein tyrosine kinase (AXL) antagonist; antiinflammatory, anticarcinogenic , antidiabetic agent; rheumatoid arthritis, vascular disease; breast, renal, endometrial, ovarian carcinoma, or myeloid leukemia | AXL, TYRO3, FLT3 | AXL 1/4885MKNK1 690/4885MKNK2 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.